Completed PHASE4 INTERVENTIONAL 2-arm NCT00220701

Escitalopram in the Treatment of Dysthymic Disorder, Double Blind

Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder

Sponsor: Forest Laboratories

Updated 6 times since 2017 Last updated: Oct 13, 2015 Started: Jun 30, 2002 Primary completion: Nov 30, 2008 Completion: Jan 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Dysthymic Disorder and is currently completed. Forest Laboratories leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories
St. Luke's-Roosevelt Hospital Center

Data source: St. Luke's-Roosevelt Hospital Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States